Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab for the Treatment of Locally Advanced or Metastatic Cancer

Trial Status: active

This phase I trial compares the drug levels of the standard dosing schedule (of either nivolumab or pembrolizumab) to an extended interval dosing schedule. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The extended interval dosing schedule will give the same dose of drug but will wait double the amount of time to give the next dose compared to the standard dosing interval. The purpose of this study is to determine if drug levels in both groups are above a target level that represents the level at which the drug should most likely produce its effect. Giving nivolumab or pembrolizumab less often while maintaining the drug effectiveness may help patients save time and money.